HAC (Russian)
RSCI (Russian)
EBSCO
DOI (USA)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

Polypragmasia in ophthalmic practice

DOI: https://doi.org/10.29296/25877305-2018-07-08
Download full text PDF
Issue: 
7
Year: 
2018

Professor L. Moshetova(2), MD, Academician of the Russian Academy of Sciences; M. Soshina(1); Professor D. Sychev(1), MD, Corresponding Member of the Russian Academy of Sciences; K. Turkina(1), Candidate of Medical Sciences; A. Lopareva(2) 1-Russian Medical Academy of Continuing Professional Education, Moscow 2-I.M. Sechenov First Moscow State Medical University (Sechenov University)

The paper provides a discussion of the clinical case of female patient P. aged 70 years, who applied for examination to the Advisory Department, Eye Hospital, with the previously verified diagnosis of grade 1a open-angle glaucoma, early cataract, and mild hypermetropia. During instillations of the local formulation of a β-adrenoblocker and an α-adrenomimetic in combination with paroxetine (an antidepressant of the selective serotonin reuptake inhibitor group), the patient developed weakness, hypotension, and bradycardia (blood pressure, 100/60 mm Hg; heart rate, 58 beats/min). In this case, there was a serious adverse reaction that was significantly associated with the adverse drug interaction according to the Horn–Hansten scale).

Keywords: 
ophthalmology
β-blockers
thymolol
polypragmasia
glaucoma
CYP2D6
paroxetine



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Walckies D., Van der Heyden J., Tafforeau J. Factors associated with excessive polypharmacy in older people // Arch. Public Health. – 2015; 73: 50.
  2. Polipragmazija v klinicheskoj praktike: problema i reshenija. Pod red. D.A. Sycheva / SPb: TsOP «Professija», 2016; s. 9.
  3. Oftal'mologija: natsional'noe rukovodstvo. Pod red. S.E. Avetisova, E.A. Egorova, L.K. Moshetovoj, V.V. Neroeva, H.P. Tahchidi / M.: GEOTAR-Media, 2013; s. 767–9.
  4. Il'ina E.S., Bogova O.T., Gorbatenkova S.V. i dr. Padenie patsienta starcheskogo vozrasta kak neblagoprijatnoe sobytie, svjazannoe s primeneniem lekarstvennyh sredstv: klinicheskoe nabljudenie // Rats. farmakoter. v kardiol. – 2017; 13 (2): 203–6.
  5. Korte J.-M., Kaila T., Saari M. Systemic bioavailability and cardiopulmonary effects of 0.5% timololeyedrops // Graefe's Arch. Clin. Exp. Ophthalmol. – 2002; 240: 430–5.
  6. Abdrashitov R.H., Gil'deeva G.N., Ramenskaja G.V. i dr. Obzor suschestvujuschih metodik otsenki aktivnosti CYP2D6 s primeneniem ekzogennyh i endogennyh markerov // Farmakokinetika i farmakodinamika. – 2015; 1: 4–11.
  7. Volotinen M., Turpeinen M., Tolonen A. et al. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6 // Drug Metabol. Disposition. – 2007; 35: 1135–41.
  8. Chaukina S.V. Kliniko-farmakologicheskie aspekty metabolizma lekarstvennyh sredstv pod dejstviem izofermenta tsitohroma R-450 CYP2D6 // Trudnyj patsient. – 2008; 14 (5): 31–3.
  9. Volotinen M., Korjamo T., Tolonen A. et al. Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes // Basic Clin. Pharmacol.Toxicol. – 2010; 106: 302–9.
  10. Bertelsen K., Venkatakrishnan K., Von Moltke L. et al. Apparent mechanism- based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine // Drug Metabol. Disposition. – 2003; 31: 289–93.
  11. Mäenpää J., Volotinen-Maja M., Kautiainen H. et al. Paroxetine markedly increases plasma concentrations of ophthalmic timolol; CYP2D6 inhibitors may increase the risk of cardiovascular adverse effects of 0.5% timolol eye drops // Drug Metabol. Disposition. – 2014; 42: 2068–76.
  12. Mäenpää J., Pelkonen O. Cardiac safety of ophthalmic timolol // Expert Opin. Drug Safety. – 2016; 15: 1549–61.
  13. Huber M., Kölzsch M., Stahlmann R. Ophthalmic drugs as part of polypharmacy in nursing home residents with glaucoma // Drugs Aging. – 2013; 30: 31–8.
  14. Horn J., Hansten P., Chan L. Proposal for a new tool to evaluate drug interaction cases // Ann. Pharmacother. – 2007; 41 (4): 674–80.
  15. Kazakov A.S. Opredelenie stepeni dostovernosti prichinno-sledstvennoj svjazi «Nezhelatel'naja reaktsija – vzaimodejstvie lekarstvennyh sredstv» // Rus. med. zhurn. – 2013; 5: 38–43.
  16. Sychev D.A., Otdelenov V.A., Krasnova N.M. i dr. Polipragmazija: vzgljad klinicheskogo farmakologa // Ter. arh. – 2016; 12: 94–102.